1800 244 735

Helpline (02) 9874 9777

Generation HD1 trial halted

Huntington’s Associations across Australia and the rest of the world have learned today that the Roche clinical trial called Phase III Generation HD1 has been halted, not by Roche, but by an independent data monitoring committee.

The detailed reasons for this decision are not yet available, but those participating on the trial of the drug (known as Tominersen) are being contacted individually by the research teams to let them know this tough news.

We, like you, are extremely disappointed by this decision as so many hopes were riding on a successful trial outcome for a new and effective drug. We know that Roche and its Australian research partners will be communicating more details as soon as they are available. Please remember however, that there are more trials underway, and more still in the pipeline.

HD research funding is high relative to the number of people with HD, as it is seen as a potential gateway to better understanding other neurological diseases.

While this doesn’t make today’s news any easier, please remember that both hope and work for a cure, or a way to prevent HD is a huge priority for a large body of researchers across many different countries and many research disciplines.

Here is a link to the statement put out by the Roche team.

If you would like to read some more head over to HD Buzz.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest News and Stories

OUR SUBMISSION to the Joint Standing Committee on the NDIS inquiry into Independent Assessments

Published date: 6 April, 2021

Huntington’s Associations in NSW/ACT, QLD, WA, SA/NT and TAS have partnered with other groups representing people with various neurological diseases to make a joint submission to the Joint Standing Committee on the National Disability Insurance Scheme inquiry into independent assessments under the NDIS. In summary, we do not support the introduction of independent assessments in ... Read more

WAVE PRECISION-HD clinical trials stopped

Published date: 6 April, 2021

An open letter to the Australian Huntington’s community following the 29 March 2021 press release from Wave Life Sciences: On March 29, 2021, Wave Life Sciences issued a press release regarding their PRECISION-HD clinical trials, which are ongoing in Australia and several other countries globally. The key information from the press release is that for ... Read more

An Open Letter to the Australian Huntington’s Community

Published date: 25 March, 2021

Since the news from Roche came out, Australian clinicians, state organisation leaders, and Huntington’s researchers have been meeting on teleconferences to discuss what this means for the Australian Huntington’s disease community.

Generation HD1 trial halted

Published date: 23 March, 2021

The Roche clinical trial called Phase III Generation HD1 has been halted, not by Roche, but by an independent data monitoring committee.

HD Spotlight on Robyn Russell

Published date: 22 March, 2021

Huntington's NSW ACT Board Member and Chair of the Community Advisory Committee shares her story with us. Read more here.

HD News Autumn 2021

Published date: 22 March, 2021

Read our Autumn edition of HD News.